The global microbiome therapeutics market size is expected to reach USD 1,066.8 million by 2030, garnering a CAGR of 35.32% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rise in prevalence of target diseases such as gastrointestinal diseases, diabetes, and immunological indications is anticipated to drive growth. The adoption of fecal microbial transplant and the availability of FMT in form of capsules has enhanced the acceptance of microbiome therapeutics amongst patients with C. difficile infection. Furthermore, increasing R&D investments and government support are anticipated to further drive the market.
FMT has demonstrated a considerable success rate in the treatment of patients with recurrent C. difficile infection. Thus, the growing prevalence of the condition is expected to escalate the demand for microbiome therapies. For instance, as per Therapeutic Advancements in Gastroenterology Journal, in 2022, after initial occurrence, 25-65% of the patients in the U.S. experience recurrent CDI which makes the treatment complex.
There has been increasing demand to understand the human microbiome to be able to transform the potential of the microbiome for use in therapeutics. This has led to an increase in R&D which has been driving the presence of a stronger pipeline in the market. Candidates such as CH-0601, and M-008 are under development for diabetes treatment. Moreover, companies are receiving heightened funding from investors owing to enhanced interest in the field. For instance, in July 2021, Vedanta Biosciences received funding of USD 68 million for phase III development of its product VE303 for high-risk CDI treatment.
Key players operating in the global market are engaged in extensive research to gain an advantage over other players. The companies are engaged in taking efforts to develop and manufacture products to be used for therapies. Numerous products are in the initial stages of trials and are expected to be developed and used in the market. For instance, in 2021, Ferring Pharmaceuticals and Rebiotix announced Phase III data of their candidate RBX2660 for the reduction in recurring C. difficile infection. The candidate further has a fast track, orphan, and breakthrough therapy designations from the FDA.
Request a free sample copy or view report summary: Microbiome Therapeutics Market Report
By type, the FMT segment held the largest market share in 2022 owing to its use as a therapeutic option in the treatment of recurrent C. difficile infection
By application, the C. difficile segment held the largest share due to the use of microbiome therapeutics in the treatment of recurrent infections
North America dominated the global market in 2022 and is anticipated to be the fastest growing region owing to the high adoption rate of novel therapeutics and the presence of regulatory support
Partnerships between big pharma companies and smaller companies that are developing microbiome therapeutics are highly common which allows these companies to receive funding and use the expertise of big pharma these companies
Key market players include OpenBiome, Seres Therapeutics Inc., 4D Pharma Plc., Locus Biosciences, Inc., Enterome SA, Finch Therapeutics Group, Inc., Intralytix, Inc., Microbiotica, Second Genome, Rebiotix Inc., and Vedanta Bioscience, Inc.
Grand View Research has segmented the global microbiome therapeutics market based on type, application, and region:
Microbiome Therapeutics Type Outlook (Revenue, USD Million, 2018 - 2030)
Microbiome Therapeutics Application Type Outlook (Revenue, USD Million, 2018 - 2030)
Inflammatory Bowel Disease
Microbiome Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
List of Key Players in Microbiome Therapeutics Market
Seres Therapeutics Inc.
4D Pharma plc.
Locus Biosciences, Inc.
Finch Therapeutics Group, Inc.
Vedanta Bioscience, Inc.
GET A FREE SAMPLE
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
"The quality of research they have done for us has been excellent..."